Børge G. Nordestgaard

164.8k total citations · 35 hit papers
953 papers, 65.2k citations indexed

About

Børge G. Nordestgaard is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Børge G. Nordestgaard has authored 953 papers receiving a total of 65.2k indexed citations (citations by other indexed papers that have themselves been cited), including 359 papers in Surgery, 294 papers in Endocrinology, Diabetes and Metabolism and 220 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Børge G. Nordestgaard's work include Lipoproteins and Cardiovascular Health (285 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (242 papers) and Cancer, Lipids, and Metabolism (102 papers). Børge G. Nordestgaard is often cited by papers focused on Lipoproteins and Cardiovascular Health (285 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (242 papers) and Cancer, Lipids, and Metabolism (102 papers). Børge G. Nordestgaard collaborates with scholars based in Denmark, United Kingdom and United States. Børge G. Nordestgaard's co-authors include Anne Tybjærg‐Hansen, Marianne Benn, Stig E. Bojesen, Anette Varbo, Anne Langsted, Ruth Frikke‐Schmidt, Peter Schnohr, Shoaib Afzal, Paul M. Ridker and Robert J. Glynn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Børge G. Nordestgaard

924 papers receiving 63.7k citations

Hit Papers

Rosuvastatin to Prevent V... 2007 2026 2013 2019 2008 2009 2007 2010 2014 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
    2008 4.7k citations Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine profile →
  2. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
    2009 2.9k citations Paul M. Ridker, Eleanor Danielson et al. profile →
  3. Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
    2007 1.6k citations Børge G. Nordestgaard, Marianne Benn et al. profile →
  4. Lipoprotein(a) as a cardiovascular risk factor: current status
    2010 1.3k citations Børge G. Nordestgaard, M. John Chapman et al. European Heart Journal profile →
  5. Triglycerides and cardiovascular disease
    2014 1.0k citations Børge G. Nordestgaard, Anette Varbo profile →
  6. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
    2011 887 citations Henry N. Ginsberg, Pierre Amarenco et al. European Heart Journal profile →
  7. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
    2014 867 citations Stefan Stender, Børge G. Nordestgaard et al. profile →
  8. Statin Use and Reduced Cancer-Related Mortality
    2012 773 citations Børge G. Nordestgaard et al. New England Journal of Medicine profile →
  9. Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
    2012 759 citations Anette Varbo, Marianne Benn et al. Journal of the American College of Cardiology profile →
  10. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
    2009 751 citations Paul M. Ridker, Eleanor Danielson et al. profile →
  11. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
    2016 738 citations Børge G. Nordestgaard profile →
  12. Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
    2014 697 citations Børge G. Nordestgaard, Anne Tybjærg‐Hansen et al. New England Journal of Medicine profile →
  13. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
    2020 641 citations Seth J. Baum, Børge G. Nordestgaard et al. New England Journal of Medicine profile →
  14. Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
    2008 623 citations Børge G. Nordestgaard et al. New England Journal of Medicine profile →
  15. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
    2009 543 citations Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine profile →
  16. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies
    2017 467 citations Anette Varbo, Børge G. Nordestgaard et al. European Heart Journal profile →
  17. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
    2013 462 citations Anette Varbo, Marianne Benn et al. profile →
  18. Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
    2012 453 citations Marianne Benn, Gerald F. Watts et al. profile →
  19. Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
    2013 415 citations Anne Tybjærg‐Hansen, Børge G. Nordestgaard et al. Journal of the American College of Cardiology profile →
  20. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
    2016 387 citations Børge G. Nordestgaard, Anne Langsted profile →
  21. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
    2012 362 citations Børge G. Nordestgaard, Anne Tybjærg‐Hansen et al. European Heart Journal profile →
  22. Worldwide Prevalence of Familial Hypercholesterolemia
    2020 349 citations Anette Varbo, Børge G. Nordestgaard et al. Journal of the American College of Cardiology profile →
  23. Mortality Attributable to Smoking Among HIV-1–Infected Individuals: A Nationwide, Population-Based Cohort Study
    2012 347 citations Shoaib Afzal, Børge G. Nordestgaard et al. profile →
  24. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
    2019 339 citations Børge G. Nordestgaard et al. profile →
  25. Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification: A Study of the General Population
    2012 287 citations Peter Lange, Jacob Louis Marott et al. American Journal of Respiratory and Critical Care Medicine profile →
  26. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci
    2017 285 citations Stefan Stender, Børge G. Nordestgaard et al. profile →
  27. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
    2021 204 citations Camilla Ditlev Lindhardt Johannesen, Martin Bødtker Mortensen et al. Journal of the American College of Cardiology profile →
  28. High-density lipoprotein revisited: biological functions and clinical relevance
    2022 185 citations Børge G. Nordestgaard, Alberico L. Catapano et al. European Heart Journal profile →
  29. The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults
    2021 177 citations Peter Schnohr, Børge G. Nordestgaard et al. European Heart Journal profile →
  30. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study
    2021 138 citations Anders Berg Wulff, Gorm Boje Jensen et al. European Heart Journal profile →
  31. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality
    2023 98 citations Anders Berg Wulff, Børge G. Nordestgaard et al. European Heart Journal profile →
  32. Neutrophil counts and cardiovascular disease
    2023 90 citations Børge G. Nordestgaard, Anne Tybjærg‐Hansen et al. European Heart Journal profile →
  33. Lipoprotein(a) and cardiovascular disease
    2024 72 citations Børge G. Nordestgaard, Anne Langsted profile →
  34. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
    2025 21 citations Børge G. Nordestgaard et al. profile →
  35. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
    2025 16 citations François Mach, Jeanine E. Roeters van Lennep et al. Atherosclerosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Børge G. Nordestgaard Denmark 120 27.1k 18.8k 16.7k 10.4k 8.8k 953 65.2k
Christie M. Ballantyne United States 126 29.4k 1.1× 16.9k 0.9× 19.9k 1.2× 9.0k 0.9× 4.2k 0.5× 1.1k 66.6k
Nader Rifai United States 122 21.1k 0.8× 16.5k 0.9× 21.5k 1.3× 21.7k 2.1× 6.4k 0.7× 455 77.6k
John J.P. Kastelein Netherlands 130 43.5k 1.6× 24.2k 1.3× 19.0k 1.1× 7.2k 0.7× 3.7k 0.4× 830 70.7k
Rory Collins United Kingdom 86 15.0k 0.6× 9.8k 0.5× 23.5k 1.4× 7.1k 0.7× 4.6k 0.5× 245 62.1k
Aaron R. Folsom United States 139 11.1k 0.4× 10.3k 0.5× 26.9k 1.6× 9.6k 0.9× 8.4k 1.0× 867 75.6k
Julie E. Buring United States 128 10.9k 0.4× 12.5k 0.7× 15.8k 0.9× 10.8k 1.0× 4.0k 0.5× 602 66.5k
Steve E. Humphries United Kingdom 94 14.3k 0.5× 10.0k 0.5× 10.0k 0.6× 6.0k 0.6× 4.5k 0.5× 872 42.3k
Frank M. Sacks United States 108 16.9k 0.6× 15.4k 0.8× 15.4k 0.9× 6.0k 0.6× 2.7k 0.3× 417 63.1k
Russell P. Tracy United States 122 13.3k 0.5× 11.6k 0.6× 23.2k 1.4× 19.5k 1.9× 8.6k 1.0× 674 87.8k
Naveed Sattar United Kingdom 132 12.7k 0.5× 22.9k 1.2× 15.0k 0.9× 13.9k 1.3× 3.2k 0.4× 1.2k 73.0k

Countries citing papers authored by Børge G. Nordestgaard

Since Specialization
Citations

This map shows the geographic impact of Børge G. Nordestgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Børge G. Nordestgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Børge G. Nordestgaard more than expected).

Fields of papers citing papers by Børge G. Nordestgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Børge G. Nordestgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Børge G. Nordestgaard. The network helps show where Børge G. Nordestgaard may publish in the future.

Co-authorship network of co-authors of Børge G. Nordestgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Børge G. Nordestgaard. A scholar is included among the top collaborators of Børge G. Nordestgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Børge G. Nordestgaard. Børge G. Nordestgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jensen, Jesper Møller, Helle Kanstrup, Niels Peter Rønnow Sand, et al.. (2025). Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry. European Heart Journal. 46(46). 5062–5072. 1 indexed citations
2.
Langsted, Anne, Børge G. Nordestgaard, Caroline Kistorp, et al.. (2025). Prevalence of obesity among adult patients with congenital heart disease: A population-based study. International Journal of Cardiology. 425. 133032–133032. 2 indexed citations
3.
4.
MacDougall, Diane, Anne Tybjærg-Hansen, Joshua W. Knowles, et al.. (2025). Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. European Heart Journal. 46(44). 4762–4775. 8 indexed citations
5.
Mach, François, Jeanine E. Roeters van Lennep, Lâle Tokgözoğlu, et al.. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 409. 120479–120479. 16 indexed citations breakdown →
6.
Larsen, Lykke, Sarah C. W. Marott, Eskild Landt, et al.. (2025). Alpha-1 antitrypsin deficiency and risk of sleep apnea: a nationwide cohort study. European Archives of Oto-Rhino-Laryngology. 282(5). 2679–2686. 1 indexed citations
7.
Olsén, Thomas, Kirsten B. Holven, Erik Arnesen, et al.. (2024). Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting. SHILAP Revista de lepidopterología. 19. 100726–100726. 1 indexed citations
8.
Johannesen, Camilla Ditlev Lindhardt, Anne Langsted, Børge G. Nordestgaard, & Martin Bødtker Mortensen. (2024). Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. Journal of the American College of Cardiology. 83(23). 2262–2273. 20 indexed citations
9.
Jensen, Gorm Boje, Morten Grønbæk, Magnus T. Jensen, et al.. (2024). Type of Alcohol and Blood Pressure: The Copenhagen General Population Study. The American Journal of Medicine. 137(9). 857–864.e4. 3 indexed citations
10.
Afzal, Shoaib, et al.. (2023). From plasma triglycerides to triglyceride metabolism: effects on mortality in the Copenhagen General Population Study. European Heart Journal. 44(39). 4174–4182. 16 indexed citations
11.
12.
Gellert‐Kristensen, Helene, Tom G. Richardson, George Davey Smith, et al.. (2020). Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology. 72(3). 845–856. 160 indexed citations
13.
Balling, Mie, Shoaib Afzal, Anette Varbo, et al.. (2020). VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. Journal of the American College of Cardiology. 76(23). 2725–2735. 123 indexed citations
14.
Wulff, Anders Berg, Børge G. Nordestgaard, & Anne Tybjærg‐Hansen. (2018). APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk. Arteriosclerosis Thrombosis and Vascular Biology. 38(3). 660–668. 79 indexed citations
15.
Kobylecki, Camilla J., Shoaib Afzal, & Børge G. Nordestgaard. (2017). Plasma Urate, Cancer Incidence, and All-Cause Mortality: A Mendelian Randomization Study. Clinical Chemistry. 63(6). 1151–1160. 31 indexed citations
16.
Wulff, Anders Berg & Børge G. Nordestgaard. (2014). Lipids And Lipoproteins. Clinical Chemistry and Laboratory Medicine (CCLM). 52(Supplement). 7 indexed citations
17.
Lee, Julie, Morten Dahl, & Børge G. Nordestgaard. (2011). Genetically Lowered Microsomal Epoxide Hydrolase Activity and Tobacco-Related Cancer in 47,000 Individuals. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1673–1682. 8 indexed citations
18.
Nordestgaard, Børge G., M. John Chapman, Kausik K. Ray, et al.. (2010). Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. 31(23). 2844–2853. 1277 indexed citations breakdown →
19.
Ridker, Paul M., Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, et al.. (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 359(21). 2195–2207. 4712 indexed citations breakdown →
20.
Dahl, Morten, et al.. (2001). Elevated Plasma Fibrinogen Associated with Reduced Pulmonary Function and Increased Risk of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 164(6). 1008–1011. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christie M. Ballantyne Breakdown of academic impact, for papers by Nader Rifai Breakdown of academic impact, for papers by John J.P. Kastelein Breakdown of academic impact, for papers by Rory Collins Breakdown of academic impact, for papers by Aaron R. Folsom Breakdown of academic impact, for papers by Julie E. Buring Breakdown of academic impact, for papers by Steve E. Humphries Breakdown of academic impact, for papers by Frank M. Sacks Breakdown of academic impact, for papers by Russell P. Tracy Breakdown of academic impact, for papers by Naveed Sattar
Rankless by CCL
2026